Adam H Schechter Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 3 days, 18 hours ago
Adam H Schechter has an estimated net worth of at least $40.9 million*, as of June 17, 2026. They own 107,234 shares of LH stock. They have sold 49,684 shares of LH stock since 2021, for an estimated $13.0 million.
Adam H Schechter $LH SEC Form 4 Insider Trading
Adam H Schechter has filed a total of 8 insider trades in $LH since 2021. Their most recent trade was a sale of 5,903 shares, made on May 11, 2026. Their largest trade was a sale of 8,705 shares, made on Mar 03, 2026. We estimate that they now own 107,234 shares of $LH, worth an estimated $27.9 million.
Insider Trading at $LH
There have been a total of 112 insider trades reported at $LH since 2021, with 3,586 shares purchased and 305,651 shares sold. The most active insider traders in $LH stock have been Der Vaart Sandra D Van, Glenn A Eisenberg, and Peter J Wilkinson. The most recent trade was a sale of 762 shares reported by Kathryn W Kyle (EVP, Chief Legal Officer), made on Jun 08, 2026.
History of Insider Stock Trades by Adam H Schechter
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
LH
|
Sale | 5,903 | May 11, 2026 | May 13, 2026, 9:30 a.m. |
|
LH
|
Sale | 8,705 | Mar 03, 2026 | March 5, 2026, 9:57 a.m. |
|
LH
|
Sale | 5,273 | Feb 11, 2026 | Feb. 13, 2026, 2:13 p.m. |
|
LH
|
Sale | 5,745 | Nov 11, 2025 | Nov. 13, 2025, 9:47 a.m. |
|
LH
|
Sale | 5,643 | Aug 11, 2025 | Aug. 13, 2025, 12:29 p.m. |
|
LH
|
Sale | 6,105 | May 12, 2025 | May 13, 2025, 10:01 a.m. |
|
LH
|
Sale | 6,121 | Feb 11, 2025 | Feb. 13, 2025, 12:49 p.m. |
|
LH
|
Sale | 6,189 | Nov 11, 2024 | Nov. 13, 2024, 9:16 a.m. |
$LH Executives and Stock Owners with Insider Trades
-
Der Vaart Sandra D Van, EVP, Chief Legal Officer
-
Glenn A Eisenberg, Chief Financial Officer, EVP
-
Peter J Wilkinson, SVP, Chief Accounting Officer
-
Mark S Schroeder, EVP, President-Diagnostics Lab
-
Adam H Schechter, President & CEO
-
Amy B. Summy, EVP, Chief Marketing Officer
-
Mark S Schroeder, EVP, Pres Diagnostics & COO
-
Jonathan C Meltzer, EVP, Operations
-
Brian J Caveney, EVP, Pres of ED, CMO & CSO
-
Brian J Caveney, EVP, President of Diagnostics
-
Lance Berberian, EVP, CIO & CTO
-
Paul R Kirchgraber, CEO, Covance Drug Development
-
Glenn A Eisenberg, Executive Vice President
-
Jonathan P. Divincenzo, EVP, Pres, Central Labs & Intl
-
Kathryn W Kyle, EVP, Chief Legal Officer
-
Der Vaart Sandra D Van, EVP, Corporate Affairs
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.